3 completed. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 3 |
Follow Antibody-mediated Rejection: new trials by email Literature Review of Antibody-mediated Rejection trials Research Report on Antibody-mediated Rejection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Desensitization in Kidney Allograft Using Daratumumab Daratumumab dose escalation, Daratumumab full dose - Allosensitization, Kidney Transplant Rejection | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 21 | 2020-02-18 | 2024-03-19 |
| Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant Clazakizumab - Kidney Failure, Chronic, End-Stage Renal Disease | Phase 1 / Phase 2 | Completed | Stanley Jordan, MD | 20 | 2018-02-27 | 2026-10-30 |
| Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant Clazakizumab - Antibody-mediated Rejection, Kidney Transplant; Complications | Phase 1 / Phase 2 | Completed | Stanley Jordan, MD | 10 | 2018-02-21 | 2025-05-06 |
Kidney Failure, Chronic (1) · Rejection, Psychology (1)
Behavior (1) · Chronic Disease (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1) · Social Behavior (1) · Urogenital Diseases (1) · Urologic Diseases (1)
clazakizumab (2)
Stanley Jordan, MD (2) · Assistance Publique - Hôpitaux de Paris (1)
United States (2) · France (1)
Stanley Jordan, MD (2) · Marie Matignon, MD (1)